Finance

Lists
XFOR:NASDAQ
X4 Pharmaceuticals Inc
$3.35
0.00%
(0.00) 1D
$3.35
0.00% (0.00)
After hours
Closed: Nov 2, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XFOR...
Open
$3.40
High
$3.47
Low
$3.26
Mkt. cap
332.14M
Avg. vol.
855.03K
Volume
0.00
52-wk high
$4.83
52-wk low
$2.43
EPS
-$1.24
Beta
0.46
Shares outstanding
99.15M
No. of employees
45
Open
$3.40
High
$3.47
Low
$3.26
Mkt. cap
332.14M
Avg. vol.
855.03K
Volume
0.00
52-wk high
$4.83
52-wk low
$2.43
EPS
-$1.24
Beta
0.46
Shares outstanding
99.15M
No. of employees
45
News stories
From web sources and news partners
About X4 Pharmaceuticals Inc
CEO-
Employees45
FoundedMar 13, 2019
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitex4pharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to XFOR in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for XFOR in the last 3 months.
Highest
Current $3.35
$12.00 (+258.21%)
Average
$11.00 (+228.36%)
Lowest
$10.00 (+198.51%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Condulis
Stifel Nicolaus
Buy
Maintained
$10.00
+198.5%
10/30/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$11.00
+228.4%
10/30/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$12.00
+258.2%
09/08/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
$10.00
+198.5%
08/07/2026
Thomas Smith
Leerink Partners
Buy
Initiated
$12.00
+258.2%
06/02/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$14.00
+317.9%
11/21/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.76M
2.57M
2.71M
8.81M
Cost of goods sold
351.00K
364.00K
598.00K
1.62M
Cost of revenue
351.00K
364.00K
598.00K
1.62M
Research and development expenses
15.84M
18.72M
15.45M
15.08M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.19M
7.38M
6.93M
8.50M
Operating expense
24.02M
26.10M
22.38M
23.58M
Total operating expenses
24.37M
26.47M
22.98M
25.20M
Operating income
-22.61M
-23.90M
-20.27M
-16.39M
Other non operating income
-980.00K
-25.00K
94.00K
421.00K
EBT including unusual items
-29.84M
-23.92M
-20.24M
-16.16M
EBT excluding unusual items
-24.94M
-24.12M
-20.20M
-16.16M
Income tax expense
-30.00K
-
-
2.00K
Effective tax rate
0.10%
-
-
-0.01%
Other operating expenses
-
-
-
-
Net income
-29.82M
-23.92M
-20.24M
-16.16M
Net profit margin
-1,689.24%
-931.66%
-747.45%
-183.48%
Earnings per share
-0.69
-0.22
-0.16
-0.13
Interest and investment income
901.00K
1.98M
2.10M
1.98M
Interest expense
-2.26M
-2.19M
-2.13M
-2.16M
Net interest expenses
-1.36M
-201.00K
-29.00K
-185.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.39M
-23.68M
-20.05M
-15.39M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps